Pinto 2012.

Methods	Design: randomised, placebo‐controlled, parallel‐group trial
Participants	Number assigned: 185 children (macrolide n = 88, placebo n = 97) Age in months (mean ± SD): macrolide: 3.08 ± 2.23, placebo: 3.12 ± 2.29 Setting: secondary care
Interventions	Indication: acute bronchiolitis Type of macrolide: azithromycin Route: per oral Dose per day: 10 mg/kg Duration of treatment: 7 days Total treatment dose: 394 mg (current weight in macrolide group used)
Outcomes	Adverse events stated as an outcome in trial registration/protocol/paper: no Adverse events ascertainment: unclear Adverse events: not reported Antimicrobial resistance: not reported Death: not reported
Funding sources	Supported by Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul
Notes	Concomitant medication: yes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Sequence generation not described.
Allocation concealment (selection bias)	Unclear risk	Allocation not described.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Unclear if placebo was identical appearing
Blinding of outcome assessment (detection bias) All outcomes	Low risk	No relevant outcomes reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	1 participant in placebo group lost to follow‐up.
Selective reporting (reporting bias)	High risk	Adverse events not stated as an outcome, unclear ascertainment, and no reporting of adverse events.
Other bias	Low risk	None were identified.